Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) Director Sells 5,230 Shares of Company Stock

Key Points

• Halozyme director Matthew Posard sold 5,230 shares at an average price of $108.54, generating $567,664.20. The sale, conducted under a pre-arranged Rule 10b5-1 plan, reduced his holdings by 8.89% to 53,609 shares.
• Halozyme shares recently traded at $109.86, near their 52-week high of $116.85, while the company reported quarterly earnings and revenue that exceeded analyst expectations. Revenue rose 47.7% year over year, and management issued fiscal 2026 EPS guidance of $8.65–$9.00.
• Institutional investors own 97.79% of the stock, and analysts maintain a broadly positive outlook with a consensus “Moderate Buy” rating, despite an average price target of $91.20.

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) Director Matthew Posard sold 5,230 shares of the business's stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $108.54, for a total transaction of $567,664.20. Following the completion of the sale, the director directly owned 53,609 shares in the company, valued at approximately $5,818,720.86. This trade represents a 8.89% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Halozyme Therapeutics Stock Performance

Shares of HALO stock traded up $2.92 during trading on Friday, reaching $109.86. 2,587,868 shares of the company's stock traded hands, compared to its average volume of 1,931,317. The firm's 50-day moving average is $102.94 and its 200 day moving average is $81.25. The company has a market capitalization of $12.47 billion, a P/E ratio of 32.79, a PEG ratio of 0.42 and a beta of 0.88. Halozyme Therapeutics, Inc. has a 1 year low of $61.22 and a 1 year high of $116.85. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, beating analysts' consensus estimates of $1.79 by $0.49. The business had revenue of $481.00 million during the quarter, compared to analyst estimates of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. Halozyme Therapeutics's revenue was up 47.7% compared to the same quarter last year. During the same period in the previous year, the business earned $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Equities research analysts expect that Halozyme Therapeutics, Inc. will post 8.25 EPS for the current year.

Institutional Investors Weigh In On Halozyme Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE bought a new position in shares of Halozyme Therapeutics in the 2nd quarter worth $214,504,000. William Blair Investment Management LLC purchased a new position in Halozyme Therapeutics in the second quarter worth $196,540,000. Royal London Asset Management Ltd. grew its position in Halozyme Therapeutics by 12.4% in the second quarter. Royal London Asset Management Ltd. now owns 1,810,815 shares of the biopharmaceutical company's stock worth $141,732,000 after acquiring an additional 200,262 shares in the last quarter. Norges Bank bought a new position in Halozyme Therapeutics in the fourth quarter valued at $128,201,000. Finally, Jupiter Topco LLC bought a new position in Halozyme Therapeutics in the second quarter valued at $105,570,000. 97.79% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on HALO shares. HC Wainwright reissued a "buy" rating and issued a $115.00 price target on shares of Halozyme Therapeutics in a report on Wednesday, September 2nd. Benchmark reaffirmed a "buy" rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. Weiss Ratings raised shares of Halozyme Therapeutics from a "buy (b-)" rating to a "buy (b)" rating in a report on Monday, August 31st. Citizens Jmp increased their target price on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a "market outperform" rating in a research note on Friday, August 7th. Finally, Citigroup reissued a "market outperform" rating on shares of Halozyme Therapeutics in a report on Friday, August 7th. Nine equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Halozyme Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $91.20.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of injectable medicines. The company's primary platform, ENHANZE, uses recombinant human hyaluronidase to temporarily modify tissue beneath the skin, allowing certain drugs and biologics that are traditionally delivered by intravenous infusion to be administered by subcutaneous injection.

Halozyme licenses its technology to pharmaceutical and biotechnology companies, which incorporate it into their own therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.